

July 21, 2022

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (Prime Market of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Osamu Okuda
Inquiries to: Toshiya Sasai
Head of Corporate Communications Dept.
Tel: +81-(0)3-3273-0554

F. Hoffmann-La Roche Announces Half Year Results 2022

F. Hoffmann-La Roche Ltd. (hereafter “Roche”) [Head Office: Basel, Switzerland. CEO: Severin Schwan] announced today its half year results 2022 (January 1 – June 30, 2022).

Roche owns 59.89% of Chugai’s outstanding shares (61.14% of voting rights) as of the end of June 2022.

Its investor update and presentation materials can be found on its website (<https://www.roche.com/>).

Chugai’s performance for the period of January 1 to June 30, 2022 is included in the announced Roche Group’s results.

[Investor Updates](#)

[Reporting](#)

###